AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23390653 — intervention group
Group type: COMPARATOR
Intervention: Traditional methods of treatment
Number of subjects: 100
Study 19751357 — intervention group
Group type: EXPERIMENTAL
Intervention: Inion GTR(TM) Biodegradable Membrane System
Number of subjects: 15
Study 19751357 — intervention group
Group type: COMPARATOR
Intervention: Geistlich resorbable bilayer Bio‐Gide((R)) membrane
Number of subjects: 15
Study 19751357 — intervention group
Group type: EXPERIMENTAL
Intervention: Both membranes
Number of subjects: 15
Study 17136555 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar scissors
Number of subjects: 138
Study 17136555 — intervention group
Group type: COMPARATOR
Intervention: Blunt dissection
Number of subjects: 138
Study 15228194 — intervention group
Group type: EXPERIMENTAL
Intervention: Males and females within the same linguistic groups
Number of subjects: 0
Study 15228194 — intervention group
Group type: EXPERIMENTAL
Intervention: Males of the two groups and females of the two groups
Number of subjects: 0
Study 12205254 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose (0.1 mL of 24%) administered orally up to 3 times, 2 minutes apart for every invasive procedure during a 7-day period
Number of subjects: 107
Study 12205254 — intervention group
Group type: COMPARATOR
Intervention: Sterile water administered orally up to 3 times, 2 minutes apart for every invasive procedure during a 7-day period
Number of subjects: 107
Study 10491709 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal vibrotactile display
Number of subjects: 0
Study 10491709 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatio-temporal vibrotactile display
Number of subjects: 0
Study 10491709 — intervention group
Group type: COMPARATOR
Intervention: Visual‐Tactile (VT) conditions
Number of subjects: 0
Study 10491709 — intervention group
Group type: COMPARATOR
Intervention: Visual‐Alone (VA) conditions
Number of subjects: 0
Study 10491709 — intervention group
Group type: COMPARATOR
Intervention: Tactile‐Alone (TA) conditions
Number of subjects: 0
Study 7662240 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg yohimbine
Number of subjects: 54
Study 2704600 — intervention group
Group type: EXPERIMENTAL
Intervention: B subunit
Number of subjects: 412
Study 2704600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412
Study 509959 — intervention group
Group type: EXPERIMENTAL
Intervention: One-contact-per-cycle schedule
Number of subjects: 0
Study 509959 — intervention group
Group type: COMPARATOR
Intervention: Two-contact-per-cycle schedule
Number of subjects: 0
Study 509959 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific symptom inquiry
Number of subjects: 0
Study 509959 — intervention group
Group type: COMPARATOR
Intervention: General inquiry
Number of subjects: 0
Study 30909680 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiocochlicoside (group A) along with paracetamol and lornoxicam I.V.
Number of subjects: 70
Study 30909680 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B) without thiocochlicoside, receiving paracetamol and lornoxicam I.V.
Number of subjects: 70
Study 28216644 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal lifestyle intervention
Number of subjects: 1555
Study 28216644 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care
Number of subjects: 1555
Study 25837041 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic lung sealant (ELS) plus medical treatment
Number of subjects: 95
Study 25837041 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment alone
Number of subjects: 95
Study 22417199 — intervention group
Group type: EXPERIMENTAL
Intervention: 3L‐1UB group (three‐set leg exercises and single‐set upper body exercises)
Number of subjects: 21
Study 22417199 — intervention group
Group type: COMPARATOR
Intervention: 1L‐3UB group (single‐set leg exercises and three‐set upper body exercises)
Number of subjects: 21
Study 22417199 — intervention group
Group type: EXPERIMENTAL
Intervention: 3L‐1UB group
Number of subjects: 21
Study 22417199 — intervention group
Group type: COMPARATOR
Intervention: 1L‐3UB group
Number of subjects: 21
Study 22417199 — intervention group
Group type: EXPERIMENTAL
Intervention: 3L‐1UB group and 1L‐3UB group
Number of subjects: 21
Study 22905666 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural tramadol (3 mg/kg)
Number of subjects: 10
Study 22905666 — intervention group
Group type: COMPARATOR
Intervention: Epidural lignocaine (4 mg/kg)
Number of subjects: 10
Study 22905666 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural tramadol
Number of subjects: 10
Study 22905666 — intervention group
Group type: COMPARATOR
Intervention: Epidural lignocaine
Number of subjects: 10
Study 19623429 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-opening cannula (SOC)
Number of subjects: 31
Study 19623429 — intervention group
Group type: COMPARATOR
Intervention: Frontal-opening cannula (FOC)
Number of subjects: 31
Study 19623429 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SOC and FOC
Number of subjects: 31
Study 17704869 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg PO, Metoclopramide 10 mg, Dexamethasone 4 mg, Ondansetron 4 mg IV
Number of subjects: 205
Study 14980173 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin alpha (activated)
Number of subjects: 0
Study 11798012 — intervention group
Group type: EXPERIMENTAL
Intervention: Panax ginseng (PG) - 2 g/day dried root equivalent
Number of subjects: 0
Study 11798012 — intervention group
Group type: EXPERIMENTAL
Intervention: Eleutherococcus senticosus (ES) - 4 g/day dried root equivalent
Number of subjects: 0
Study 11798012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9684719 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior approach for RF modification of AV node
Number of subjects: 33
Study 9684719 — intervention group
Group type: COMPARATOR
Intervention: Posterior approach for RF modification of AV node
Number of subjects: 33
Study 9684719 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover to anterior approach
Number of subjects: 33
Study 9684719 — intervention group
Group type: COMPARATOR
Intervention: Stepwise approach from posterior to anterior
Number of subjects: 33
Study 7849498 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (300 micrograms orally, 1 h prior to morphine)
Number of subjects: 15
Study 3347080 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 ml of absolute alcohol per kg of body weight)
Number of subjects: 30
Study 3347080 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (orange juice and vodka essence)
Number of subjects: 30
Study 3347080 — intervention group
Group type: COMPARATOR
Intervention: Control (orange juice)
Number of subjects: 30
Study 31158914 — intervention group
Group type: EXPERIMENTAL
Intervention: Alliance Focused Training (AFT)
Number of subjects: 15
Study 29557839 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity functional anaerobic and progressive resistance training of the lower limbs (n = 8)
Number of subjects: 17
Study 29557839 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (n = 9)
Number of subjects: 17
Study 28657451 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated dietitians (DD)
Number of subjects: 545
Study 28657451 — intervention group
Group type: COMPARATOR
Intervention: Trained hospital dietitian (THD)
Number of subjects: 545
Study 28657451 — intervention group
Group type: COMPARATOR
Intervention: Existing practice (EP)
Number of subjects: 545
Study 25827430 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day low-sodium diet (51.3 mmol sodium/day)
Number of subjects: 100
Study 25827430 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day high-sodium diet (307.8 mmol sodium/day)
Number of subjects: 100
Study 25827430 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day high-sodium diet with potassium supplementation (307.8 mmol sodium/day and 60 mmol potassium/day)
Number of subjects: 100
Study 25827430 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline log-transformed UAGT and UAGT/Cr ratio
Number of subjects: 100
Study 25827430 — intervention group
Group type: COMPARATOR
Intervention: High-sodium intervention
Number of subjects: 100
Study 25827430 — intervention group
Group type: COMPARATOR
Intervention: Low-sodium to high-sodium intervention
Number of subjects: 100
Study 23359520 — intervention group
Group type: EXPERIMENTAL
Intervention: Pycnogenol® 150 mg/day
Number of subjects: 64
Study 23359520 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study 20798386 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose isoflavones (20 g of soy protein containing 160 mg of total isoflavones)
Number of subjects: 33
Study 20798386 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 g whole milk protein)
Number of subjects: 33
Study 20798386 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose isoflavones
Number of subjects: 33
Study 20798386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 18781287 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical azithromycin ophthalmic solution 1% plus warm compresses
Number of subjects: 21
Study 18781287 — intervention group
Group type: COMPARATOR
Intervention: Warm compresses alone
Number of subjects: 21
Study 16569248 — intervention group
Group type: EXPERIMENTAL
Intervention: Early administration of atropine during dobutamine stress echocardiogram (group C at 40 mcg/kg/min of dobutamine)
Number of subjects: 121
Study 14599854 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous daclizumab infusions (anti-IL-2 receptor alpha)
Number of subjects: 15
Study 14599854 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous daclizumab formulation
Number of subjects: 15
Study 14599854 — intervention group
Group type: COMPARATOR
Intervention: Intravenous daclizumab infusions (6-week intervals)
Number of subjects: 15
Study 14599854 — intervention group
Group type: COMPARATOR
Intervention: Intravenous daclizumab infusions (2- to 4-week intervals)
Number of subjects: 15
Study 10952473 — intervention group
Group type: COMPARATOR
Intervention: Buflomedil
Number of subjects: 0
Study 10952473 — intervention group
Group type: COMPARATOR
Intervention: Naftidrofuryl
Number of subjects: 0
Study 10952473 — intervention group
Group type: COMPARATOR
Intervention: Pentoxifylline
Number of subjects: 0
Study 9197448 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 5 microg/24 h
Number of subjects: 112
Study 9197448 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 10 microg/24 h
Number of subjects: 112
Study 9197448 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 5 microg/24 h and 10 microg/24 h
Number of subjects: 112
Study 7570621 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation exposure to toluene diisocyanate (TDI) vapors
Number of subjects: 10
Study 7570621 — intervention group
Group type: COMPARATOR
Intervention: Unexposed individuals
Number of subjects: 10
Study 3739806 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco
Number of subjects: 0
Study 3739806 — intervention group
Group type: COMPARATOR
Intervention: Control (non-smoking sessions)
Number of subjects: 0
Study 31657625 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehomecare (THC) system for 3 months
Number of subjects: 92
Study 31657625 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 92
Study 30021554 — intervention group
Group type: EXPERIMENTAL
Intervention: supervised exercise
Number of subjects: 500
Study 30021554 — intervention group
Group type: EXPERIMENTAL
Intervention: facility access
Number of subjects: 500
Study 30021554 — intervention group
Group type: EXPERIMENTAL
Intervention: self‐monitoring
Number of subjects: 500
Study 30021554 — intervention group
Group type: EXPERIMENTAL
Intervention: group‐based active living counseling
Number of subjects: 500
Study 27702719 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod skin peptide (CSPE)
Number of subjects: 60
Study 27702719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 24884807 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest Pain Choice (CPC) decision aid
Number of subjects: 0
Study 24884807 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 22958541 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led support
Number of subjects: 418
Study 22958541 — intervention group
Group type: COMPARATOR
Intervention: Lay-trainer support
Number of subjects: 418
Study 20419336 — intervention group
Group type: EXPERIMENTAL
Intervention: PICI% <or= 74%
Number of subjects: 190
Study 18362100 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod liver oil (10 g containing 2.2 g of n-3 EFAs)
Number of subjects: 97
Study 18362100 — intervention group
Group type: COMPARATOR
Intervention: Placebo (air-filled identical capsules)
Number of subjects: 97
Study 17114971 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic shock
Number of subjects: 120
Study 17114971 — intervention group
Group type: COMPARATOR
Intervention: Monophasic shock
Number of subjects: 120
Study 14626187 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupoint pressing (AAP)
Number of subjects: 45
Study 14626187 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 45
Study 10612774 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass (on pump) with intermittent antegrade warm blood cardioplegia
Number of subjects: 60
Study 10612774 — intervention group
Group type: COMPARATOR
Intervention: Surgery on the beating heart (off pump)
Number of subjects: 60
Study 9193837 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 140
Study 9193837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 1358003 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose esmolol (300 micrograms.kg‐1.min‐1)
Number of subjects: 20
Study 1358003 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose esmolol (200 micrograms.kg‐1.min‐1)
Number of subjects: 20
Study 1358003 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose esmolol (100 micrograms.kg‐1.min‐1)
Number of subjects: 20
Study 1358003 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 20
Study 2997306 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentopril (CGS 13945) 125 mg capsules administered in the fasting state
Number of subjects: 8
Study 2997306 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentopril (CGS 13945) 125 mg capsules administered after ingestion of a standardized meal
Number of subjects: 8
Study 30887250 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06650808 at dose levels ≤2.0 mg/kg
Number of subjects: 40
Study 30887250 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06650808
Number of subjects: 40
Study 31119173 — intervention group
Group type: EXPERIMENTAL
Intervention: VR combined with exercise imagery (running group)
Number of subjects: 52
Study 31119173 — intervention group
Group type: COMPARATOR
Intervention: VR distraction (driving group)
Number of subjects: 52
Study 30236568 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm intravenous fluids (Ringer's solution at 38°C)
Number of subjects: 0
Study 30236568 — intervention group
Group type: COMPARATOR
Intervention: Room temperature intravenous fluids (Ringer's solution)
Number of subjects: 0
Study 26934850 — intervention group
Group type: EXPERIMENTAL
Intervention: Icodextrin instillation in the abdominal cavity
Number of subjects: 283
Study 26934850 — intervention group
Group type: COMPARATOR
Intervention: Standard surgery without icodextrin
Number of subjects: 283
Study 25008546 — intervention group
Group type: EXPERIMENTAL
Intervention: Tozadenant 120 mg twice daily
Number of subjects: 420
Study 25008546 — intervention group
Group type: EXPERIMENTAL
Intervention: Tozadenant 180 mg twice daily
Number of subjects: 420
Study 25008546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study 22067661 — intervention group
Group type: EXPERIMENTAL
Intervention: NGX-4010 (capsaicin 8% patch)
Number of subjects: 494
Study 22067661 — intervention group
Group type: COMPARATOR
Intervention: Low-dose capsaicin (0.04% control patch)
Number of subjects: 494
Study 22067661 — intervention group
Group type: EXPERIMENTAL
Intervention: NGX-4010 (30-minute application)
Number of subjects: 494
Study 22067661 — intervention group
Group type: COMPARATOR
Intervention: Low-dose capsaicin (30-minute control)
Number of subjects: 494
Study 22067661 — intervention group
Group type: EXPERIMENTAL
Intervention: NGX-4010 (60-minute application)
Number of subjects: 494
Study 22067661 — intervention group
Group type: COMPARATOR
Intervention: Low-dose capsaicin (60-minute control)
Number of subjects: 494
Study 22067661 — intervention group
Group type: EXPERIMENTAL
Intervention: Total NGX-4010 group
Number of subjects: 494
Study 19400487 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypobaric bupivacaine 0.15% 4.5 mg (3 ml)
Number of subjects: 150
Study 19400487 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypobaric bupivacaine 0.15% 6.0 mg (4 ml)
Number of subjects: 150
Study 19400487 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypobaric bupivacaine 0.15% 7.5 mg (5 ml)
Number of subjects: 150
Study 17225043 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocational-oriented intervention (education, reassurance, motivation, vocational counselling)
Number of subjects: 89
Study 17225043 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 89
Study 17225043 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocational-oriented intervention
Number of subjects: 89
Study 17225043 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes (life satisfaction, disability, fear avoidance behaviour, expectancy)
Number of subjects: 89
Study 14722542 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine N-butyl bromide (40 mg)
Number of subjects: 120
Study 14722542 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (control)
Number of subjects: 120
Study 11533544 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethylamide 6% (MW 200 kDa SD 0.5)
Number of subjects: 126
Study 11533544 — intervention group
Group type: COMPARATOR
Intervention: Modified fluid gelatine (MFG) 4% (MW 30 kDa)
Number of subjects: 126
Study 9609575 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy
Number of subjects: 63
Study 8193885 — intervention group
Group type: EXPERIMENTAL
Intervention: FSE sequence (TR = 4000 ms, effective TE = 100 ms, 2 NEX)
Number of subjects: 35
Study 8193885 — intervention group
Group type: COMPARATOR
Intervention: T2‐weighted SE sequence (TR = 2000 ms, TE = 90 ms, 1‐2 NEX)
Number of subjects: 35
Study 8193885 — intervention group
Group type: EXPERIMENTAL
Intervention: FSE sequence
Number of subjects: 35
Study 3400079 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin (100 mg)
Number of subjects: 12
Study 3400079 — intervention group
Group type: EXPERIMENTAL
Intervention: Etretinate (100 mg)
Number of subjects: 12
Study 3400079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30821829 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy for 5 years (HPS trial)
Number of subjects: 45029
Study 30821829 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident stroke
Number of subjects: 45029
Study 30821829 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident transient ischemic attack, myocardial infarction, heart failure, and new-onset diabetes
Number of subjects: 45029
Study 27262301 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC-chemotherapy
Number of subjects: 1322
Study 27262301 — intervention group
Group type: EXPERIMENTAL
Intervention: ECOG 0
Number of subjects: 1322
Study 26701648 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (rt-PA)
Number of subjects: 109
Study 26701648 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rt-PA)
Number of subjects: 109
Study 26701648 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-randomization arterial obstruction attenuation
Number of subjects: 109
Study 23132904 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based exercise intervention for 10 weeks
Number of subjects: 121
Study 21838092 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral complete nasal packing without airway (Group A)
Number of subjects: 90
Study 21838092 — intervention group
Group type: COMPARATOR
Intervention: Nasal packing with airway on one side (Group B)
Number of subjects: 90
Study 21838092 — intervention group
Group type: COMPARATOR
Intervention: Nasal packing with airway on both sides (Group C)
Number of subjects: 90
Study 19786682 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 264
Study 19786682 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 264
Study 16857111 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic endoprosthesis insertion
Number of subjects: 0
Study 16857111 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expandable metallic prostheses
Number of subjects: 0
Study 15136391 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized acupuncture treatment
Number of subjects: 36
Study 15136391 — intervention group
Group type: COMPARATOR
Intervention: Mock transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 36
Study 11532742 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (150 microg)
Number of subjects: 10
Study 11532742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9247389 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide
Number of subjects: 22
Study 9247389 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 22
Study 9247389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 8319490 — intervention group
Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.5% ophthalmic suspension
Number of subjects: 113
Study 8319490 — intervention group
Group type: COMPARATOR
Intervention: Placebo (LE vehicle)
Number of subjects: 113
Study 3546274 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 34
Study 3546274 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 34
Study 31615861 — intervention group
Group type: EXPERIMENTAL
Intervention: Community members
Number of subjects: 1648
Study 31615861 — intervention group
Group type: COMPARATOR
Intervention: Responders
Number of subjects: 1648